Providence's above-state obesity rate, two active low-income primary care HPSAs, an unverified state Medicaid position, and a local market with no published self-pay price at all.
Providence's adult obesity prevalence is 34.4% (CDC PLACES 2025 release, BRFSS 2023) 1, above Rhode Island's statewide 31.6% 2. The city holds 194,710 residents inside a 1,684,071-person metro, with a 7.5% uninsured rate and a $61,797 median household income, the lowest in this batch 3456.
Providence is home to two academic hospital systems and a medical school. It is also a city where no clinic publishes what GLP-1 treatment costs 11.
RI EOHHS's public pharmacy and provider-manual pages, including the Medicaid Provider Manual's Pharmacy Coverage Policy, the Drug Utilization Review Program page, and the Subregulatory Policies page, do not surface explicit GLP-1-for-weight-loss coverage language, prior-authorization criteria, or an obesity-indication exclusion. All three were checked directly on August 28, 2026 10.
Treat any specific Rhode Island Medicaid GLP-1 claim, in either direction, as unverified until confirmed with EOHHS pharmacy at (401) 784-8100. We are not filling that gap with a guess.
A search for Providence clinics that publish their own self-pay GLP-1 pricing came up empty: no medical spa or weight-loss clinic based in the city discloses a price on its own site. Clinic websites, state licensing records, and local business coverage were checked, including a Providence Business News site search that returned zero results for local GLP-1 or weight-loss clinic coverage 11.
That opacity is itself the finding: patients comparison-shopping locally have nothing public to compare against. Astra's price is published and flat everywhere it treats: $68/month for compounded semaglutide and $118/month for compounded tirzepatide, both on 12-month plans billed annually at $816 and $1,416. That is the same number in Providence as in every other state Astra serves, with no local rate and no consult required to see it.
HRSA's national Primary Care HPSA file, pulled August 28, 2026 from a dataset refreshed the day before, shows two active designations touching Providence: "LI-Providence City PC HPSA," a geographic Low-Income Population designation scored 10 with a designated population of 68,560, and a facility-based designation at Providence Community Health Centers scored 13 with a designated population of 82,572 78. Both are current, meaning a substantial share of the city's low-income residents face a federally recognized primary-care access gap.
Specialist capacity is not the problem. Providence is anchored by Rhode Island's two largest academic systems, Brown University Health, which runs Rhode Island Hospital and The Miriam Hospital, and Care New England, which runs Women & Infants Hospital, plus Brown's Warren Alpert Medical School, giving the city above-typical specialist density for its size 9. HRSA scores no obesity-medicine or endocrinology category, so that is a qualitative read rather than a numeric shortage figure.
For many residents the barrier is reaching a doctor to start treatment, not finding a specialist once referred. Telehealth is that first door. Astra treats patients in all 50 states, including Rhode Island.
Astra treats patients in Rhode Island through state-licensed physicians.
Astra's price doesn't change by city — semaglutide is $68/month and tirzepatide is $118/month on a 12-month plan, the same in Providence as everywhere else Astra treats. A fair local comparison isn't possible from public information: an extensive check of Providence clinic websites, state licensing records, and local business coverage found no medical spa or weight-loss clinic physically located in the city that publishes its own self-pay GLP-1 pricing. That absence — not a specific competing number — is the honest answer: Providence's local market for this treatment is largely price-opaque, and Astra's flat rate is public before you start.
Rhode Island's Medicaid program (EOHHS) publishes pharmacy and provider-manual pages at eohhs.ri.gov, but as of this review those pages do not spell out specific coverage terms, prior-authorization criteria, or an obesity-indication exclusion for GLP-1 medications like Ozempic, Wegovy, or Zepbound. The honest answer is: unconfirmed from public documents — call EOHHS pharmacy at (401) 784-8100 for a definitive answer on your plan. Astra operates as a self-pay telehealth option and doesn't depend on Medicaid coverage.
Providence's adult obesity rate is 34.4% (CDC PLACES, crude prevalence, 2023 survey data) — meaningfully above Rhode Island's statewide rate of 31.6% (CDC BRFSS, 2023). Providence holds roughly 18% of the state's population, so an obesity rate that runs nearly 3 points above the state average means the capital carries more of Rhode Island's obesity burden than its population share alone would predict. (Providence city sits entirely inside Providence County, so a city-vs-county comparison isn't very telling since they share a name and largely the same footprint — city-vs-state is the more useful contrast.)
Federal HRSA data (checked 2026-08-28) show two active primary-care shortage-area designations touching Providence: a geographic low-income-population HPSA (score 10, about 68,560 residents) and a facility-based HPSA at Providence Community Health Centers (score 13, about 82,572 residents). Providence actually has above-typical specialist density thanks to Brown University Health and Care New England's academic hospital systems, so the real bottleneck for many residents isn't a lack of specialists — it's simply getting a primary-care appointment, which is usually the first step toward a weight-loss prescription. Telehealth removes that first step by connecting patients directly to a licensed prescriber.
Yes. Astra is licensed to treat patients in all 50 states, including Rhode Island, so Providence residents start treatment the same way patients anywhere else in the country do — with the same $68/month semaglutide or $118/month tirzepatide pricing on a 12-month plan.
Last reviewed:
Educational information, not medical advice. Treatment requires evaluation by a licensed physician.